Characterization of anti-CD20 monoclonal antibody produced by transgenic silkworms (Bombyx mori)

References

• Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10:301-16; PMID:20414204; http://dx.doi.org/10.1038/nri2761
   PubMed Web of Science ®Google Scholar
• Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010; 9:767-74; PMID:20811384; http://dx.doi.org/10.1038/nrd3229
   PubMed Web of Science ®Google Scholar
• Reichert JM. Marketed therapeutic antibodies compendium. MAbs 2012; 4:413-5; PMID:22531442; http://dx.doi.org/10.4161/mabs.19931
   PubMed Web of Science ®Google Scholar
• Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012; 12:278-87; PMID:22437872; http://dx.doi.org/10.1038/nrc3236
   PubMed Web of Science ®Google Scholar
• Ghaderi D, Zhang M, Hurtado-Ziola N, Varki A. Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation. Biotechnol Genet Eng Rev 2012; 28:147-75; PMID:22616486; http://dx.doi.org/10.5661/bger-28-147
   PubMed Web of Science ®Google Scholar
• Zhang RY, Shen WD. Monoclonal antibody expression in mammalian cells. Methods Mol Biol 2012; 907:341-58; PMID:22907362; http://dx.doi.org/10.1007/978-1-61779-974-7_20
   PubMedGoogle Scholar
• Kim JY, Kim YG, Lee GM. CHO cells in biotechnology for production of recombinant proteins: current state and further potential. Appl Microbiol Biotechnol 2012; 93:917-30; PMID:22159888; http://dx.doi.org/10.1007/s00253-011-3758-5
   PubMed Web of Science ®Google Scholar
• Houdebine LM. Production of pharmaceutical proteins by transgenic animals. Comp Immunol Microbiol Infect Dis 2009; 32:107-21; PMID:18243312; http://dx.doi.org/10.1016/j.cimid.2007.11.005
   PubMed Web of Science ®Google Scholar
• Maksimenko OG, Deykin AV, Khodarovich YM, Georgiev PG. Use of transgenic animals in biotechnology: prospects and problems. Acta Naturae 2013; 5:33-46; PMID:23556129
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhao S, Bai L, Fan J, Liu E. Expression systems and species used for transgenic animal bioreactors. Biomed Res Int 2013; 2013:580463; PMID:23586046
   PubMed Web of Science ®Google Scholar
• De Muynck B, Navarre C, Boutry M. Production of antibodies in plants: status after twenty years. Plant Biotechnol J 2010; 8:529-63; PMID:20132515; http://dx.doi.org/10.1111/j.1467-7652.2009.00494.x
   PubMed Web of Science ®Google Scholar
• Karg SR, Kallio PT. The production of biopharmaceuticals in plant systems. Biotechnol Adv 2009; 27:879-94; PMID:19647060; http://dx.doi.org/10.1016/j.biotechadv.2009.07.002
   PubMed Web of Science ®Google Scholar
• Adiguzel C, Iqbal O, Demir M, Fareed J. European community and US-FDA approval of recombinant human antithrombin produced in genetically altered goats. Clin Appl Thromb Hemost 2009; 15:645-51; PMID:19850586; http://dx.doi.org/10.1177/1076029609339748
   PubMed Web of Science ®Google Scholar
• Kling J. First US approval for a transgenic animal drug. Nat Biotechnol 2009; 27:302-4; PMID:19352350; http://dx.doi.org/10.1038/nbt0409-302
   PubMed Web of Science ®Google Scholar
• Haddley K. Taliglucerase alfa for the treatment of Gaucher's disease. Drugs Today (Barc) 2012; 48:525-32; PMID:22916340; http://dx.doi.org/10.1358/dot.2012.48.4.1788435
   PubMed Web of Science ®Google Scholar
• Grabowski GA, Golembo M, Shaaltiel Y. Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology. Mol Genet Metab 2014; 112:1-8; PMID:24630271; http://dx.doi.org/10.1016/j.ymgme.2014.02.011
   PubMed Web of Science ®Google Scholar
• Pollock DP, Kutzko JP, Birck-Wilson E, Williams JL, Echelard Y, Meade HM. Transgenic milk as a method for the production of recombinant antibodies. J Immunol Methods 1999; 231:147-57; PMID:10648934; http://dx.doi.org/10.1016/S0022-1759(99)00151-9
   PubMed Web of Science ®Google Scholar
• Zhu L, van de Lavoir MC, Albanese J, Beenhouwer DO, Cardarelli PM, Cuison S, Deng DF, Deshpande S, Diamond JH, Green L, et al. Production of human monoclonal antibody in eggs of chimeric chickens. Nat Biotechnol 2005; 23:1159-69; PMID:16127450; http://dx.doi.org/10.1038/nbt1132
   PubMed Web of Science ®Google Scholar
• Garabagi F, McLean MD, Hall JC. Transient and stable expression of antibodies in Nicotiana species. Methods Mol Biol 2012; 907:389-408; PMID:22907365; http://dx.doi.org/10.1007/978-1-61779-974-7_23
   PubMedGoogle Scholar
• Rodriguez M, Perez L, Gavilondo JV, Garrido G, Bequet-Romero M, Hernandez I, Huerta V, Cabrera G, Pérez M, Ramos O, et al. Comparative in vitro and experimental in vivo studies of the anti-epidermal growth factor receptor antibody nimotuzumab and its aglycosylated form produced in transgenic tobacco plants. Plant Biotechnol J 2013; 11:53-65; PMID:23046448; http://dx.doi.org/10.1111/pbi.12006
   PubMed Web of Science ®Google Scholar
• Schuster M, Jost W, Mudde GC, Wiederkum S, Schwager C, Janzek E, Altmann F, Stadlmann J, Stemmer C, Gorr G. In vivo glyco-engineered antibody with improved lytic potential produced by an innovative non-mammalian expression system. Biotechnol J 2007; 2:700-8; PMID:17427997; http://dx.doi.org/10.1002/biot.200600255
   PubMedGoogle Scholar
• Kircheis R, Halanek N, Koller I, Jost W, Schuster M, Gorr G, Hajszan K, Nechansky A. Correlation of ADCC activity with cytokine release induced by the stably expressed, glyco-engineered humanized Lewis Y-specific monoclonal antibody MB314. MAbs 2012; 4:532-41; PMID:22665069; http://dx.doi.org/10.4161/mabs.20577
   PubMed Web of Science ®Google Scholar
• Decker EL, Parsons J, Reski R. Glyco-engineering for biopharmaceutical production in moss bioreactors. Front Plant Sci 2014; 5:346; PMID:25071817; http://dx.doi.org/10.3389/fpls.2014.00346
   PubMed Web of Science ®Google Scholar
• Cox KM, Sterling JD, Regan JT, Gasdaska JR, Frantz KK, Peele CG, Black A, Passmore D, Moldovan-Loomis C, Srinivasan M, et al. Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nat Biotechnol 2006; 24:1591-7; PMID:17128273; http://dx.doi.org/10.1038/nbt1260
   PubMed Web of Science ®Google Scholar
• Banno Y, Shimada T, Kajiura Z, Sezutsu H. The silkworm-an attractive BioResource supplied by Japan. Exp Anim 2010; 59:139-46; PMID:20484847; http://dx.doi.org/10.1538/expanim.59.139
   PubMed Web of Science ®Google Scholar
• Kato T, Kajikawa M, Maenaka K, Park EY. Silkworm expression system as a platform technology in life science. Appl Microbiol Biotechnol 2010; 85:459-70; PMID:19830419; http://dx.doi.org/10.1007/s00253-009-2267-2
   PubMed Web of Science ®Google Scholar
• Usami A, Suzuki T, Nagaya H, Kaki H, Ishiyama S. Silkworm as a host of baculovirus expression. Curr Pharm Biotechnol 2010; 11:246-50; PMID:20210748; http://dx.doi.org/10.2174/138920110791112013
   PubMed Web of Science ®Google Scholar
• Tomita M. Transgenic silkworms that weave recombinant proteins into silk cocoons. Biotechnol Lett 2011; 33:645-54; PMID:21184136; http://dx.doi.org/10.1007/s10529-010-0498-z
   PubMed Web of Science ®Google Scholar
• Usami A, Ishiyama S, Enomoto C, Okazaki H, Higuchi K, Ikeda M, Yamamoto T, Sugai M, Ishikawa Y, Hosaka Y, et al. Comparison of recombinant protein expression in a baculovirus system in insect cells (Sf9) and silkworm. J Biochem 2011; 149:219-27; PMID:21113054; http://dx.doi.org/10.1093/jb/mvq138
   PubMed Web of Science ®Google Scholar
• Ueda Y, Sakurai T, Yanai A. Homogeneous production of feline interferon in silkworm by replacing single amino acid code in signal peptide region in recombinant baculovirus and characterization of the product. J Vet Med Sci 1993; 55:251-8; PMID:7685640; http://dx.doi.org/10.1292/jvms.55.251
   PubMed Web of Science ®Google Scholar
• Okano F, Satoh M, Ido T, Okamoto N, Yamada K. Production of canine IFN-gamma in silkworm by recombinant baculovirus and characterization of the product. J Interferon Cytokine Res 2000; 20:1015-22; PMID:11096459; http://dx.doi.org/10.1089/10799900050198462
   PubMed Web of Science ®Google Scholar
• Tamura T, Thibert C, Royer C, Kanda T, Abraham E, Kamba M, Komoto N, Thomas JL, Mauchamp B, Chavancy G, et al. Germline transformation of the silkworm Bombyx mori L. using a piggyBac transposon-derived vector. Nat Biotechnol 2000; 18:81-4; PMID:10625397; http://dx.doi.org/10.1038/71978
   PubMed Web of Science ®Google Scholar
• Wurm FM. Human therapeutic proteins from silkworms. Nat Biotechnol 2003; 21:34-5; PMID:12511906; http://dx.doi.org/10.1038/nbt0103-34
   PubMed Web of Science ®Google Scholar
• Tomita M, Munetsuna H, Sato T, Adachi T, Hino R, Hayashi M, Shimizu K, Nakamura N, Tamura T, Yoshizato K. Transgenic silkworms produce recombinant human type III procollagen in cocoons. Nat Biotechnol 2003; 21:52-6; PMID:12483223; http://dx.doi.org/10.1038/nbt771
   PubMed Web of Science ®Google Scholar
• Hino R, Tomita M, Yoshizato K. The generation of germline transgenic silkworms for the production of biologically active recombinant fusion proteins of fibroin and human basic fibroblast growth factor. Biomaterials 2006; 27:5715-24; PMID:16905183; http://dx.doi.org/10.1016/j.biomaterials.2006.07.028
   PubMed Web of Science ®Google Scholar
• Ogawa S, Tomita M, Shimizu K, Yoshizato K. Generation of a transgenic silkworm that secretes recombinant proteins in the sericin layer of cocoon: production of recombinant human serum albumin. J Biotechnol 2007; 128:531-44; PMID:17166611; http://dx.doi.org/10.1016/j.jbiotec.2006.10.019
   PubMed Web of Science ®Google Scholar
• Iizuka M, Ogawa S, Takeuchi A, Nakakita S, Kubo Y, Miyawaki Y, Hirabayashi J, Tomita M. Production of a recombinant mouse monoclonal antibody in transgenic silkworm cocoons. FEBS J 2009; 276:5806-20; PMID:19740109; http://dx.doi.org/10.1111/j.1742-4658.2009.07262.x
   PubMed Web of Science ®Google Scholar
• Tatematsu K, Kobayashi I, Uchino K, Sezutsu H, Iizuka T, Yonemura N, Tamura T. Construction of a binary transgenic gene expression system for recombinant protein production in the middle silk gland of the silkworm Bombyx mori. Transgenic Res 2010; 19:473-87; PMID:19789990; http://dx.doi.org/10.1007/s11248-009-9328-2
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8:34-47; PMID:18064051; http://dx.doi.org/10.1038/nri2206
   PubMed Web of Science ®Google Scholar
• Kuo TT, Aveson VG. Neonatal Fc receptor and IgG-based therapeutics. MAbs 2011; 3:422-30; PMID:22048693; http://dx.doi.org/10.4161/mabs.3.5.16983
   PubMed Web of Science ®Google Scholar
• Rath T, Kuo TT, Baker K, Qiao SW, Kobayashi K, Yoshida M, Roopenian D, Fiebiger E, Lencer WI, Blumberg RS. The immunologic functions of the neonatal Fc receptor for IgG. J Clin Immunol 2013; 33 Suppl 1:S9-17; PMID:22948741; http://dx.doi.org/10.1007/s10875-012-9768-y
   PubMedGoogle Scholar
• Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, Yamaguchi T. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol 2010; 184:1968-76; PMID:20083659; http://dx.doi.org/10.4049/jimmunol.0903296
   PubMed Web of Science ®Google Scholar
• Maloney DG. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med 2012; 366:2008-16; PMID:22621628; http://dx.doi.org/10.1056/NEJMct1114348
   PubMed Web of Science ®Google Scholar
• Tada M, Ishii-Watabe A, Suzuki T, Kawasaki N. Development of a cell-based assay measuring the activation of FcgammaRIIa for the characterization of therapeutic monoclonal antibodies. PLoS One 2014; 9:e95787; PMID:24752341; http://dx.doi.org/10.1371/journal.pone.0095787
   PubMed Web of Science ®Google Scholar
• Kawasaki N, Itoh S, Hashii N, Takakura D, Qin Y, Huang X, Yamaguchi T. The significance of glycosylation analysis in development of biopharmaceuticals. Biol Pharm Bull 2009; 32:796-800; PMID:19420744; http://dx.doi.org/10.1248/bpb.32.796
   PubMed Web of Science ®Google Scholar
• Sola RJ, Griebenow K. Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy. BioDrugs 2010; 24:9-21; PMID:20055529; http://dx.doi.org/10.2165/11530550-000000000-00000
   PubMed Web of Science ®Google Scholar
• Costa AR, Rodrigues ME, Henriques M, Oliveira R, Azeredo J. Glycosylation: impact, control and improvement during therapeutic protein production. Crit Rev Biotechnol 2014; 34:281-99; PMID:23919242; http://dx.doi.org/10.3109/07388551.2013.793649
   PubMed Web of Science ®Google Scholar
• Mizuochi T, Taniguchi T, Shimizu A, Kobata A. Structural and numerical variations of the carbohydrate moiety of immunoglobulin G. J Immunol 1982; 129:2016-20; PMID:6811655
   PubMed Web of Science ®Google Scholar
• Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009; 8:226-34; PMID:19247305; http://dx.doi.org/10.1038/nrd2804
   PubMed Web of Science ®Google Scholar
• Hristodorov D, Fischer R, Linden L. With or without sugar? (A)glycosylation of therapeutic antibodies. Mol Biotechnol 2013; 54:1056-68; PMID:23097175; http://dx.doi.org/10.1007/s12033-012-9612-x
   PubMed Web of Science ®Google Scholar
• Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277:26733-40; PMID:11986321; http://dx.doi.org/10.1074/jbc.M202069200
   PubMed Web of Science ®Google Scholar
• Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003; 278:3466-73; PMID:12427744; http://dx.doi.org/10.1074/jbc.M210665200
   PubMed Web of Science ®Google Scholar
• Boyd PN, Lines AC, Patel AK. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol Immunol 1995; 32:1311-8; PMID:8643100; http://dx.doi.org/10.1016/0161-5890(95)00118-2
   PubMed Web of Science ®Google Scholar
• Hodoniczky J, Zheng YZ, James DC. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog 2005; 21:1644-52; PMID:16321047; http://dx.doi.org/10.1021/bp050228w
   PubMed Web of Science ®Google Scholar
• Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 2008; 20:471-8; PMID:18606225; http://dx.doi.org/10.1016/j.coi.2008.06.007
   PubMed Web of Science ®Google Scholar
• Park EY, Ishikiriyama M, Nishina T, Kato T, Yagi H, Kato K, Yagi H, Kato K, Ueda H. Human IgG1 expression in silkworm larval hemolymph using BmNPV bacmids and its N-linked glycan structure. J Biotechnol 2009; 139:108-14; PMID:18984019; http://dx.doi.org/10.1016/j.jbiotec.2008.09.013
   PubMed Web of Science ®Google Scholar
• Dojima T, Nishina T, Kato T, Uno T, Yagi H, Kato K, Ueda H, Park EY. Improved secretion of molecular chaperone-assisted human IgG in silkworm, and no alterations in their N-linked glycan structures. Biotechnol Prog 2010; 26:232-8; PMID:19918885
   PubMed Web of Science ®Google Scholar
• Tawara T, Hasegawa K, Sugiura Y, Harada K, Miura T, Hayashi S, Tahara T, Ishikawa M, Yoshida H, Kubo K, et al. Complement activation plays a key role in antibody-induced infusion toxicity in monkeys and rats. J Immunol 2008; 180:2294-8; PMID:18250438; http://dx.doi.org/10.4049/jimmunol.180.4.2294
   PubMed Web of Science ®Google Scholar
• van der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001; 115:807-11; PMID:11843813; http://dx.doi.org/10.1046/j.1365-2141.2001.03166.x
   PubMed Web of Science ®Google Scholar
• Fukuda MN, Sasaki H, Lopez L, Fukuda M. Survival of recombinant erythropoietin in the circulation: the role of carbohydrates. Blood 1989; 73:84-9; PMID:2910371
   PubMed Web of Science ®Google Scholar
• Imai N, Higuchi M, Kawamura A, Tomonoh K, Oh-Eda M, Fujiwara M, Shimonaka Y, Ochi N. Physicochemical and biological characterization of asialoerythropoietin. Suppressive effects of sialic acid in the expression of biological activity of human erythropoietin in vitro. Eur J Biochem 1990; 194:457-62; PMID:2269277; http://dx.doi.org/10.1111/j.1432-1033.1990.tb15639.x
   PubMedGoogle Scholar
• Elliott S, Lorenzini T, Asher S, Aoki K, Brankow D, Buck L, Busse L, Chang D, Fuller J, Grant J, et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 2003; 21:414-21; PMID:12612588; http://dx.doi.org/10.1038/nbt799
   PubMed Web of Science ®Google Scholar
• Lee K, Jin X, Zhang K, Copertino L, Andrews L, Baker-Malcolm J, Geagan L, Qiu H, Seiger K, Barngrover D, et al. A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 2003; 13:305-13; PMID:12626384; http://dx.doi.org/10.1093/glycob/cwg034
   PubMed Web of Science ®Google Scholar
• Desnick RJ, Schuchman EH. Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges. Annu Rev Genomics Hum Genet 2012; 13:307-35; PMID:22970722; http://dx.doi.org/10.1146/annurev-genom-090711-163739
   PubMed Web of Science ®Google Scholar
• Altmann F, Staudacher E, Wilson IB, Marz L. Insect cells as hosts for the expression of recombinant glycoproteins. Glycoconj J 1999; 16:109-23; PMID:10612411; http://dx.doi.org/10.1023/A:1026488408951
   PubMed Web of Science ®Google Scholar
• Shi X, Jarvis DL. Protein N-glycosylation in the baculovirus-insect cell system. Curr Drug Targets 2007; 8:1116-25; PMID:17979671; http://dx.doi.org/10.2174/138945007782151360
   PubMed Web of Science ®Google Scholar
• Simmons LC, Reilly D, Klimowski L, Raju TS, Meng G, Sims P, Hong K, Shields RL, Damico LA, Rancatore P, et al. Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. J Immunol Methods 2002; 263:133-47; PMID:12009210; http://dx.doi.org/10.1016/S0022-1759(02)00036-4
   PubMed Web of Science ®Google Scholar
• Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, Kuni-Kamochi R, Nakano R, Yano K, Kakita S, et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology 2007; 17:104-18; PMID:17012310; http://dx.doi.org/10.1093/glycob/cwl057
   PubMed Web of Science ®Google Scholar
• Goetze AM, Liu YD, Zhang Z, Shah B, Lee E, Bondarenko PV, Flynn GC. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology 2011; 21:949-59; PMID:21421994; http://dx.doi.org/10.1093/glycob/cwr027
   PubMed Web of Science ®Google Scholar
• Alessandri L, Ouellette D, Acquah A, Rieser M, Leblond D, Saltarelli M, Radziejewski C, Fujimori T, Correia I. Increased serum clearance of oligomannose species present on a human IgG1 molecule. MAbs 2012; 4:509-20; PMID:22669558; http://dx.doi.org/10.4161/mabs.20450
   PubMed Web of Science ®Google Scholar
• van Beers MM, Bardor M. Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins. Biotechnol J 2012; 7:1473-84; PMID:23027660; http://dx.doi.org/10.1002/biot.201200065
   PubMed Web of Science ®Google Scholar
• Uchino K, Imamura M, Sezutsu H, Kobayashi I, Kojima K, Kanda T, Toshiki T. Evaluating promoter sequences for trapping an enhancer activity in the silkworm bombyx mori. J Insect Biotechnol Sericol 2006; 75:89-97
   Google Scholar
• Tatematsu K-I, Uchino K, Sezutsu H, Tamura T. Effect of ATG initiation codon context motifs on the efficiency of translation of mRNA derived from exogenous genes in the transgenic silkworm, Bombyx mori. SpringerPlus 2014; 3:136; PMID:25674439; http://dx.doi.org/10.1186/2193-1801-3-136
   PubMedGoogle Scholar
• Abdiche YN, Yeung YA, Chaparro-Riggers J, Barman I, Strop P, Chin SM, Pham A, Bolton G, McDonough D, Lindquist K, et al. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. MAbs 2015; 7:331-43; PMID:25658443
   PubMed Web of Science ®Google Scholar
• Myszka DG. Improving biosensor analysis. J Mol Recognit 1999; 12:279-84; PMID:10556875; http://dx.doi.org/10.1002/(SICI)1099-1352(199909/10)12:5%3c279::AID-JMR473%3e3.0.CO;2-3
   PubMed Web of Science ®Google Scholar
• Harazono A, Kawasaki N, Itoh S, Hashii N, Matsuishi-Nakajima Y, Kawanishi T, Yamaguchi T. Simultaneous glycosylation analysis of human serum glycoproteins by high-performance liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 869:20-30; PMID:18514042; http://dx.doi.org/10.1016/j.jchromb.2008.05.006
   PubMed Web of Science ®Google Scholar